OCUL · Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Market Cap
1.226B
52 Wk Range
$5.54 - $16.44
Previous Close
$5.86
Open
$5.76
Volume
2,895,423
Day Range
$5.54 - $5.95
Enterprise Value
837.9M
Cash
530.6M
Avg Qtr Burn
-65.62M
Insider Ownership
0.91%
Institutional Own.
96.95%
Qtr Updated
Sep 30th 2026
